News & Press

  1. April 23rd, 2019. VaxNewMo’s patent US15/533,733 issued and granted by the United States Patent Office.
  2. April 16th, 2019. Check out our latest review article on glycoengineering coli for bioconjugate vaccine, therapeutic and diagnostic production: https://academic.oup.com/glycob/advance-article/doi/10.1093/glycob/cwz031/5467302
  3. March 11th, 2019. VaxNewMo awarded its third Phase I SBIR/STTR grant from the NIAID to develop bioconjugate vaccines against Group B
  4. February 28th, 2019. VaxNewMo highlighted by the St. Louis Business Journal for its success in with multiple SBIR/STTR grant awards and vaccine platform – https://www.bizjournals.com/stlouis/news/2019/02/28/how-one-st-louis-biotech-startup-is-proving-its.html
  5. February 21st, 2019. VaxNewMo publishes its platform technology manuscript in Nature Communications https://www.nature.com/articles/s41467-019-08869-9
  6. January 17th, 2019. Dr. Harding presents VaxNewMo’s bioconjugation platform during the Peptalk: The Protein Science Week in San Diego, CA.
  7. June 13th, 2018. Dr. Harding presents latest VaxNewMo’s pneumococcal bioconjugate data to the FASEB Microbial Glycobiology Conference in Scottsdale, Arizona.
  8. January 13th, 2018. Dr. Harding presents VaxNewMo’s latest achievements at the Peptalk 2018: The Protein Science Week in San Diego, CA.
  9. December 20th, 2017. VaxNewMo awarded its second Phase I SBIR/STTR grant to develop a multivalent bioconjugate vaccine against Klebsiella pneumoniae.
  10. February 21st, 2017. VaxNewMo awarded its first Phase I SBIR/STTR grant to develop the most broadly encompassing pneumococcal bioconjugate vaccine.